📣 TetraKit Technologies has entered into a strategic collaboration with 3B Pharmaceuticals to co-develop a targeted alpha therapy (TAT) using astatine-211.
This partnership combines our TetraKit radiolabeling platform with 3BP’s deep expertise in drug discovery to advance a novel peptide radiopharmaceutical for oncology. The goal: to enable more effective cancer treatments through precision radiotherapy.
We’re looking forward to driving innovation in the field of alpha-emitting radionuclides and expanding the impact of next-generation radiopharmaceuticals.
More about the collaboration:
🔗 www.tetrakit.com
🔗 www.3b-pharma.com
